Lymphoma Treatment Market – By Type, By Drug Type, By Route of Administration, By Distribution Channel – Global Forecast 2025 – 2034

Lymphoma Treatment Market Size

The lymphoma treatment market size was valued at USD 8.3 billion in 2024 and is expected to reach USD 18.3 billion by 2034, growing at a CAGR of 8.4% from 2025 to 2034. Lymphoma is a form of cancer that develops from the lymphatic tissue, which is a part of the immune system of the body.
 

It occurs when lymphocytes, which are a type of white blood cells, proliferate abnormally, leading to malignancies in the lymph nodes as well as other tissues. The two primary subsets are Hodgkin lymphoma and non-Hodgkin lymphoma which are differentiated by presence of Reed Sternberg cells in Hodgkin Lymphoma. Common symptoms include lymphadenopathy associated with fever, fatigue, and loss of appetite.
 

The lymphoma treatment market worldwide is growing at a rapid pace. This is largely due to the increasing incidence of lymphoma cases across the globe. Non-Hodgkin lymphoma alone constituted over 545,000 new cases and 260,000 deaths in the year 2020 according to the Global Cancer Observatory (GLOBOCAN), and numbers are expected to increase in near future because of aging population and lifestyle choices. In addition to this, the burden of Hodgkin lymphoma is significant as well, which is more prevalent among the youth population. The treatment gap is especially critical in places where healthcare infrastructure is not well developed. The survival rates in these areas are much lower which increases the need for new treatment methods that improve the chances of survival in lower income regions.
 

Further, new treatment approaches such as CAR T-cell therapies and immune checkpoint inhibitors, which is forecasted to reach USD 189.1 billion by 2032, along with bispecific antibodies, are transforming the treatment of lymphomas. For instance, Axi-cel (Yescarta), which is a CAR T-cell therapy, demonstrated unprecedented results in the ZUMA-7 trial where 55% of patients with aggressive diffuse large B-cell lymphoma survived 4 years post treatment compared to 46% with standard treatment, marking a significant improvement over the 4-year survival rates achieved with existing therapies. Innovations such as bispecific antibodies combined with other targeted therapies are increasing access and improving results while precision medicine continues to fuel growth in the market by addressing significant health gaps.
 

 Lymphoma Treatment Market Trends

• The market is undergoing a paradigm shift as new targeted therapies are being incorporated due to growing approvals. These therapies aim at lymphoma specific molecules or pathways essential for the survival and division of malignant cells, thus making the approach more precise. Because of this, the improvements achieved in efficacy and safety ultimately improves patient outcomes and minimizes side effects associated with the treatment. This development is increasing market revenues and treatment options for different subtypes of lymphoma.
   
• For instance, the FDA gave approval to use Brukinsa in March 2024 alongside Gazyva for follicular lymphoma relapse and progression after previous lines of treatment in adults. This approval is a step forward within segmented therapies for difficult to treat lymphomas.
   
• In addition, the harmful effects of cancer treatment on healthy tissues are minimized with the use of antibody-drug conjugates (ADCs), which are now being employed more in the treatment of lymphoma due to their direct action on neoplastic tissues.
   
• For instance, Polivy (polatuzumab vedotin-piiq) by Roche was approved in combination with R-CHP to treat previously untreated DLBCL and HGBL in patients with IPI score of two or greater in April 2023. The IPI index is one of the most popular clinical markers used to estimate the prognosis of patients suffering from aggressive forms of non-Hodgkin lymphomas such as DLBCL.
   
• The market and patient access are broadened due to the rising use of biosimilars in the treatment of lymphoma because these cost less than branded biologics, thus increasing market competition.
   
• For instance, biosimilars such as Truxima and Ruxience which were earlier approved by FDA, lower the cost of treatment while maintaining comparable therapeutic efficacy to Rituxan (rituximab).
   
• Moreover, many key players are entering into the biosimilar market are further driving cost reductions. In December 2020, Amgen announced that it has received FDA approval for Riabni for the treatment of non-Hodgkin’s lymphoma along with other indications, and it was available in the U.S. from January 2021.
   

Lymphoma Treatment Market Analysis

• Non-Hodgkin lymphoma (NHL) is associated with a higher frequency than Hodgkin lymphoma which forms the basis of its predominance in the share of the market. NHL, with its large array of subtypes, captures a larger portion of the patient population in the world. Its increasing prevalence is propeling the market for this segment.
   
• GLOBOCAN estimated that around 553,389 new cases of NHL occurred throughout the globe by the year 2022 which account for considerable share of lymphomas. In contrast, Hodgkin lymphoma was expected to contribute only 82,469 new cases in the same period. The difference between the two numbers is striking and signifies NHL affecting a greater proportion of the population. This indicates a considerable unmet need regarding treatment in this segment.
   

• Rituximab (Rituxan / Mabthera), the first therapy using a monoclonal antibody for treating lymphoma was specifically directed towards the CD20 molecule on B lymphocytes. Thus, it can be used for many B cell lymphomas of which the more common ones are non-Hodgkin lymphoma (NHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
   
• Clinical Trials have shown improvement in the duration of remission with the use of Rituximab. For instance, in follicular lymphoma, patients that received Rituximab in addition to chemotherapy lived for three times longer progression-free than those that only underwent chemotherapy.
   
• Furthermore, Rituximab's advantages in increasing the duration of remission, response rates, and survival across a variety of lymphomas continue to maintain its position in this market.
   

Based on route of administration, the lymphoma treatment market is bifurcated into oral and parenteral segments. The parenteral segment accounted for the largest market share of 78.7% in 2024.
 

• Parenteral administration involves the direct injection of medication into the bloodstream which ensures that the drug is fully utilized, and the patient receives the required medicine as fast as possible. This is especially important in aggressive lymphomas that require immediate action.
   
• Furthermore, precision dosing and regulated delivery is necessary for advanced procedures such as immunotherapy, CAR T-cell therapy, and high-dose chemotherapy, which is allowed by parenteral methods. Additionally, for patients unable to take oral medications due to extreme symptoms or bowel issues, parenteral administration is the preferred method.
   
• In addition, parenteral administration is the standard, or first treatment of choice, for relapsed or refractory lymphoma cases, as they do not respond to oral alternatives effectively.
   
• With these advantages, parenteral routes of administration are preferred for relapsing or refractory lymphoma, thus, supporting its dominance in the market.
   

Based on distribution channel, the lymphoma treatment market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share of 45.9% in 2024.
 

• The market for treatment of lymphomas is largely dependent on hospital–administered therapies such as chemotherapy, immunotherapy, and CAR-T cell therapies, all of which require special preparation and handling for proper administration. The medications required for lymphoma treatment are conveniently available at hospital pharmacies.
   
• Thus, they serve as the primary distribution points for personally tailored medications and cost-intensive biologics required for treating lymphoma, making them the preferred distribution channel for lymphoma medications.
   
• Further, the growing volume of hospital admissions for specialized oncology care centers also supports the segment’s considerable market share.
   

• The country has a high prevalence of chronic diseases including HL as well as NHL.
   
• In 2024 the National Cancer Institute estimated that over 80,620 new cases of Non-Hodgkin Lymphoma (NHL) and 8,570 cases of Hodgkin lymphoma, would be diagnosed in the U.S., which highlights the treatment necessity.
   
• Furthermore, the aggressive development of new treatments such as CAR T-cell therapy and bispecific antibodies tends to significantly amplify market potential because of the FDA's rapid approval policies and ensures that patients are treated with advanced therapies in a timely manner.
   

Europe: The UK lymphoma treatment market is expected to experience steady growth from 2025 to 2034.
 

• The growing burden of lymphoma disease in the UK provides higher market need for novel treatment solutions. Research in precision medicines, immunotherapies, and CAR-T cell therapies are fulfilling the demand for better outcomes.
   
• According to Cancer Research UK, the country roughly registers Hodgkin lymphoma at around 2,200 new cases and 13,400 cases of non-Hodgkin lymphoma (NHL) every year on average for the years 2017-2019. This suggests that there were approximately 6 additional cases of Hodgkins lymphoma, and 37 more cases of NHL diagnosed each day during the period, illustrating the need for effective therapies is persistent and significant.
   
• Moreover, programs such as the Life Sciences Industrial Strategy and efforts toward Brexit-strategic devolution are improving the UK’s capacity for innovation and domestical production of treatments for lymphoma.
   

Asia Pacific: Japan lymphoma treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has highly developed pharmaceutical technologies and the rising longer-term demand for treatment for chronic conditions. Japan is set to face one of the oldest populations in the world, increasing the likelihood of age-associated diseases including lymphoma.
   
• The Japanese Society of Medical Oncology estimates approximately 30,000 new cases of lymphoma every year in Japan.
   

Middle East and Africa: The lymphoma treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• There is an increase in lymphoma cases in Saudi Arabia. According to the MDPI, lymphomas have a prevalence of roughly 10% of cancer cases in Saudi Arabia. Furthermore, in 2020 Non-Hodgkin Lymphoma (NHL) was the third most prevalent cancer in men and the sixth most prevalent cancer in women in the country.
   
• This market in Saudi Arabia is poised for remarkable growth. This great prevalence highlights the need for effective lymphoma treatment.
   
• The ongoing advancements in healthcare along with the increased awareness are expected to foster the growth of the market because innovative therapies are required to deal with the rising cases of lymphoma.
   

 Lymphoma Treatment Market Share

The market for lymphoma treatment is extremely competitive, with various pharmaceutical companies contesting for leadership in both established as well as emerging regions. Top 4 players include large multinational companies such as Roche, Bayer, Novartis, and Bristol-Myers Squibb, which dominate the market accounting for approximately 45% of market share with a portfolio of monoclonal antibodies, CAR-T cell therapies, and chemotherapy agents. Biotech firms such as Gilead and Kite Pharma are also noteworthy for their advancements in cancer immunotherapy, and targeted treatments. Additionally, smaller companies are focusing on innovative treatments, such as bispecific antibodies and novel small molecule inhibitors.
 

Lymphoma Treatment Market Companies

Some of the eminent market participants operating in the lymphoma treatment industry include:

• AstraZeneca
• Bayer
• BeiGene
• Biogen
• Bristol-Myers Squibb
• Celgene
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Gilead Sciences
• Incyte
• Johnson & Johnson
• Juno Therapeutics
• Merck
• Novartis
• Seattle Genetics
• Takeda Pharmaceutical
   
• Gilead, through its subsidiary Kite Pharma, is a leader in CAR-T therapies for lymphoma treatment, offering innovative cell-based solutions. For instance, Yescarta (axicabtagene ciloleucel) was the first CAR-T therapy approved by the FDA for relapsed/refractory large B-cell lymphoma, revolutionizing treatment options.
   
• BeiGene is expanding rapidly in the oncology space, focusing on targeted therapies for hematologic malignancies, including lymphoma. For instance, in January 2023, the FDA approved Brukinsa (zanubrutinib) for relapsed/refractory mantle cell lymphoma, reinforcing BeiGene’s presence in the market.
   

Lymphoma Treatment Industry News:

• In June 2024, the latest T-cell engaging bispecific antibody, which is given subcutaneously, EPKINLY by AbbVie, was approved by the FDA for adults with relapsed or refractory follicular lymphoma (FL) after two or more therapies. Epcoritamab's subcutaneous route of administration and bispecific antibody's novel mechanism of action will likely transform treatment paradigms for this difficult to treat cancer in the forecasted period.
   
• In May 2024, The FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who had previously received two or more lines of systemic therapy including BTK inhibitor and other treatments. With this FDA approval, we expect this to provide a novel, possibly game-changing treatment option for patients with few other options.
   

The lymphoma treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Hodgkin lymphoma
• Non-Hodgkin lymphoma

Market, By Drug Type

• Rituxan/MabThera
• Revlimid
• Imbruvica
• Adcetris
• Keytruda
• Opdivo
• Other drug types

Market, By Route of Administration

• Oral
• Parenteral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE